Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2016

View Archived Issues

FDA grants orphan drug status to BioVie's BIV-201 for ascites

Bristol-Myers Squibb initiates phase I/II trial of BMS-986183 in advanced hepatocellular carcinoma

GSK initiates phase II trial of GSK-2982772 in psoriasis

Oncology Venture incorporates oncology therapeutics spin-out 2X Oncology in U.S.

AdAlta signs manufacturing agreement for AD-114

FDA clears IND for phase I trial of Cantrixil in ovarian cancer

RespireRx announces preliminary topline data from phase IIa trial of CX-1739

Horizon Pharma to acquire Raptor Pharmaceutical

GlaxoSmithKline submits MAA for sirukumab in rheumatoid arthritis

Novel RBM20 gene mutation linked to left ventricular noncompaction cardiomyopathy

FDA gives fast track designation to niraparib, Tesaro begins rolling NDA submission

SK Biopharmaceuticals patents mGlu5 receptor PAMs

First patient dosed in Xencor's phase I study of Xmab-14045

Sunshine Lake Pharma and Calitor Sciences disclose PI3Kdelta inhibitors

Bayer Pharma describes anticancer agents

Bristol-Myers Squibb reports development of NS5B inhibitors

Amplyx Pharmaceuticals doses first patients in phase I study of antifungal agent

Janssen-Cilag submits MAA to EMA for darunavir-based single tablet regimen

MacroGenics regains rights to MGD-010 from Takeda

VCAM1 and ANGPTL4 show promise as successful pleurodesis biomarkers

Repros Therapeutics submits MAA for enclomiphene

Mutations in PRODH2 could be genetic cause of hydroxyprolinemia

PNPLA4 identified as novel causative gene for mitochondrial respiratory chain disorders

Janssen applies for emergency use assessment and listing of Ebola prime-boost vaccine regimen

FDA clears Angionetics' phase III study of Generx gene therapy

UD-009 shows efficacy in pulmonary fibrosis model

Interim topline data from phase Ib study of GED-0301 in active Crohn's disease

Brain penetration, effects on disease seen with SBC-103 in mucopolysaccharidosis IIIB

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...